Table 1.
Demographic, clinical and laboratory characteristics of groups
| PPMS (no: 24) | PRMS (no: 8) | |
|---|---|---|
| Age (median, year) (max-min) | 52.5 (31–65) | 44.5 (34–50) |
| Female/Male ratio | 1.18 | 0.6 |
| Age at the onset (median, year) (max-min) | 41.5 (23–55) | 37 (24–44) |
| Symptom of onset: no. | ||
| Motor disturbances | 13 | 5 |
| Sensory disturbances | 3 | 2 |
| Cerebellar imbalance | 5 | 0 |
| Diplopia or other brain stem symptoms | 2 | 1 |
| Bladder dysfunction | 1 | 0 |
| Optic neuritis | 0 | 0 |
| Duration of Disease (median, year) (max-min) | 7.5 (2–26) | 9 (2–13) |
| Symptom onset to diagnosis time (median, year) (max-min) | 5 (1–32) | 2.5 (2–12) |
| EDSS (median, year) (max-min) | 6 (1.5–9) | 3.5 (2–7.5) |
| CSF data (available PPMS: 17 PRMS: 8) | ||
| Oligoclonal band positivity: no. (%) | 13 (76) | 6 (75) |
| Elevated IgG index: no. (%) | 4 (23) | 5 (62) |
| Electrophysiological studies | ||
| Prolonged P100 latencies in VEP: no. (%) (available PPMS: 13 PRMS: 5) | 7 (53) | 4 (80) |
| SEP: no. (%) (available PPMS: 8 PRMS: 2) | 7 (87) | 2 (100) |
CSF, cerebrospinal fluid; EDSS, expanded disability status scale; IgG, immunoglobulin G; no., number; PPMS, primary progressive multiple sclerosis; PRMS, progressive relapsing multiple sclerosis; SEP, somatosensory evoked potentials; VEP, visual evoked potentials.